ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01.
| Entry into a Material Definitive Agreement. |
On May 10, 2017, OncoSec Medical Incorporated (OncoSec) entered
into a clinical trial collaboration and supply agreement (the
Collaboration and Supply Agreement) with MSD International GmbH,
a subsidiary of Merck (known as MSD outside the United States and
Canada) (Merck) to clinically evaluate the combination of
OncoSecs ImmunoPulse IL-12 with Mercks anti PD-1 therapy KEYTRUDA
(pembrolizumab).
Under the Collaboration and Supply Agreement, OncoSec will
sponsor and fund the Phase II multicenter study of ImmunoPulse
IL-12 in combination with KEYTRUDA in patients with histological
diagnosis of melanoma with progressive locally advanced or
metastatic disease defined as Stage III or Stage IV, who are
progressing or have progressed on an approved anti-PD-1 therapy
(the PISCES study). Merck will be responsible for manufacturing
and supplying KEYTRUDA for the PISCES study.
| Item 8.01. | Other Events. |
On May 10, 2017, OncoSec issued a press release announcing the
Collaboration and Supply Agreement. A copy of the press release
is being furnished as Exhibit 99.1 to this Current Report.
The information in Item 8.01 of this Current Report, including
the attached Exhibit 99.1 furnished herewith, is being furnished
and shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that Section. The
information in Item 8.01 of this Current Report, including
Exhibit 99.1, shall not be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
to this Current Report in such a filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit | Description | |
| 99.1 |
Press Release of OncoSec Medical Incorporated dated May 10, 2017. |
About ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS)
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses. ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS) Recent Trading Information
ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS) closed its last trading session up +0.06 at 1.13 with 575,736 shares trading hands.
